Scancell (LON:SCLP) Trading Up 7% on Insider Buying Activity

Scancell Holdings plc (LON:SCLP)’s stock price was up 7% on Wednesday after an insider bought additional shares in the company. The stock traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle purchased 44,944 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,429.48).

Scancell Price Performance

The company has a 50-day moving average price of GBX 9.38 and a two-hundred day moving average price of GBX 10.21. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market cap of £102.54 million, a PE ratio of -15.18 and a beta of 0.35.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.